EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Experimental murine invasive pulmonary aspergillosis



Experimental murine invasive pulmonary aspergillosis



American Journal of Clinical Pathology 93(4): 510-515



A new model of invasive pulmonary aspergillosis (IPA) was developed in immunosuppressed mice. Intranasal route of inoculation was used to deliver predictable number of Aspergillus flavus conidia. The LD50 was determined to be 2.7 .times. 102 viable conidia, and a combination of quantitative culture and determination of chitin content was shown to best measure the progression of pulmonary disease. The evolution of IPA in these mice conformed with what has been reported in human cases of aspergillosis; both histopathology of the pulmonary lesions and dissemination pattern resembled their human counterparts. The authors hope to use this model to study virulence mechanisms of Aspergillus and novel therapeutic methods.

(PDF emailed within 0-6 h: $19.90)

Accession: 001831880

Download citation: RISBibTeXText

PMID: 2321582

DOI: 10.1093/ajcp/93.4.510



Related references

Standardization of an experimental murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 50(10): 3501-3503, 2006

Pathological spectrum of invasive pulmonary aspergillosis. Study of pulmonary lesions of 54 autopsies and the relationship between neutrophilic response and histologic features of lesions in experimental aspergillosis. Japanese Journal of Medical Mycology 38(2): 175-181, 1997

Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 48(5): 1908-1911, 2004

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis. Antimicrobial Agents and ChemoTherapy 63(2): -, 2018

Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 50(8): 2895-2896, 2006

Role of TNF-a in pulmonary host defense in murine invasive aspergillosis. Journal of Immunology 162(3): 33-40, 1999

Effects of surgical resection of pulmonary lesions to the relapse of pulmonary aspergillosis in allogeneic hematopoietic stem cell transplant recipients with invasive pulmonary aspergillosis. Zhonghua Nei Ke Za Zhi 55(1): 31-35, 2016

Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 50(10): 3464-3466, 2006

Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. Journal of Immunology 162(3): 1633-1640, 1999

In vivo pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 445, 2003

Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Medical Mycology 49(8): 834-847, 2014

Murine model to follow hyphal development in invasive pulmonary aspergillosis. Applied Microbiology and Biotechnology: -, 2018

Effect of twice daily aerosolized nystatin on murine invasive pulmonary aspergillosis. Abstracts of the Annual Meeting of the American Society for Microbiology 83: F28, 1983

Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Annals of Hematology 82(2): 80-82, 2003

Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clinical Infectious Diseases 27(3): 437-452, 1998